Daily Archives: September 17, 2020

Komet Announces Results From Annual Shareholders’ Meeting

MONTREAL, Sept. 17, 2020 (GLOBE NEWSWIRE) — Komet Resources Inc. (“Komet” or the “Corporation”) (TSX-V: KMT) is pleased to announce the results of its annual meeting of shareholders held on September 15, 2020.

Mr. Robert Wares, Chairman and interim President of Komet, commented: “The Corporation obtained outstanding shareholder support for all tabled items, including name change to Brunswick Exploration, and we are very happy to welcome Ms. Amy Satov and Mr. Jeff Hussey to the Board of Directors. A new trading symbol for Brunswick Exploration will be announced as soon as approval from the TSX Venture Exchange is received. Closing of the current previously announced financing is expected to occur at month’s end, which will allow the company to launch its new exploration programs in New Brunswick and Quebec.”

Results from shareholders’ votes are as follows:

Election of Directors

The following persons were nominated as directors of the Corporation; the detailed voting results are as follows:

Nominees Votes For % For Withheld % Withheld
Pierre Colas 42,962,215 99.955 % 19,500 0.045 %
Jeff Hussey 42,962,215 99.955 % 19,500 0.045 %
André Le Bel 42,962,215 99.955 % 19,500 0.045 %
Amy Satov 42,962,215 99.955 % 19,500 0.045 %
Mathieu Savard 42,962,215 99.955 % 19,500 0.045 %
Robert Wares 42,962,215 99.955 % 19,500 0.045 %

Appointment of Auditors

Raymond Chabot Grant Thornton LLP, professional chartered accountants, were appointed as auditors of the Corporation for the current year:

Votes For % For Withheld % Withheld
43,077,271 100% 0  0%

Name Change

The special resolution to authorize an amendment to the Articles of the Corporation changing the name of the Corporation from “Les Ressources Komet inc. / Komet Resources Inc.” to “Brunswick Exploration Inc.” was approved as follows:

Votes For % of Votes For Votes Against % of Votes Against
42,799,715 99.577% 182,000 0.423%

Change of Head Office

The special resolution to authorize an amendment to the Articles of the Corporation changing the head office of the Corporation to the district of Montréal was approved as follows:

Votes For % of Votes For Votes Against % of Votes Against
42,799,715 99.577% 182,000 0.423%

Investor Relations/information:

Mr. Robert Wares, Chairman and interim President (r.wares@kometgold.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

ETC Announces the Final Acceptance by the U.S. Air Force of a Suite of Four Research Altitude Chambers

SOUTHAMPTON, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTC Pink: ETCC) (“ETC”) announces the final acceptance by the U.S. Air Force of a suite of four Research Altitude Chambers delivered to the 711th Human Performance Wing at Wright-Patterson Air Force Base in Dayton, OH, USA.

Valued at over $38 million, the suite of research altitude chambers allows maximum flexibility in the configuration of unique test scenarios under a wide range of environmental conditions. Three of the four chambers are “man-rated” allowing human occupancy for future initiatives. The fourth chamber can be utilized for equipment and various research testing scenarios.

ETC’s suite of chambers will support activities for the U.S. Government’s aeromedical research mission, which include:

  • Human performance assessment in moderate and high altitude conditions;
  • Aircrew equipment development, qualification and Man Rating;
  • Operationally focused aeromedical research;
  • Non-medical engineering test work for aircraft/weapons programs.

Among other things, the final contract resolution incorporated into the contract the technical provisions of an engineering change proposal that made minor modifications to the device specification to conform it to the as-delivered suite of Research Altitude Chambers, provided for the U.S. Air Force’s final acceptance, resulted in an addition to the contract base price of approximately two percent (2%), and resolved all potential claims regarding contract changes and program delay.

States Robert L. Laurent, Jr., President and CEO, “We are pleased to complete this program and in the years to come look forward to working to support the research altitude chambers and the Government’s important mission for our military personnel.”

About ETC:
ETC designs, manufactures, and sells software driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions.  Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies.  ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition.  ETC is headquartered in Southampton, PA.  For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements:
This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances.  Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions.  We base our forward-looking statements on our current expectations and projections about future events or future financial performance.  Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements.  We caution you not to place undue reliance on these forward-looking statements.

Contact: Mark Prudenti, CFO
Phone: 215-355-9100 x1531
E-mail: mprudenti@etcusa.com

Sumo Logic Announces Pricing of Initial Public Offering

Sumo Logic

SUMO | Nasdaq Listed

REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) — Sumo Logic, Inc. (“Sumo Logic”) today announced the pricing of its initial public offering of 14,800,000 shares of its common stock at a price of $22.00 per share. All of the shares are being offered by Sumo Logic. The shares are expected to begin trading on the Nasdaq Global Select Market on September 17, 2020 under the ticker symbol “SUMO.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sumo Logic, are expected to be $325.6 million. In addition, Sumo Logic has granted the underwriters a 30-day option to purchase up to an additional 2,220,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on September 21, 2020, subject to customary closing conditions.

Morgan Stanley and J.P. Morgan are acting as lead book-running managers for the offering. RBC Capital Markets and Jefferies are acting as book-running managers for the offering, and William Blair, Cowen, Piper Sandler and BTIG are acting as co-managers for the offering.

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on September 16, 2020. This offering is being made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; RBC Capital Markets, LLC, Attn: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281-8098, by telephone at 877-822-4089 or by email at equityprospectus@rbccm.com; or Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sumo Logic

Sumo Logic is the pioneer in continuous intelligence, a new category of software, which enables organizations of all sizes to address the data challenges and opportunities presented by digital transformation, modern applications, and cloud computing. The Sumo Logic Continuous Intelligence Platform™ automates the collection, ingestion, and analysis of application, infrastructure, security, and IoT data to derive actionable insights within seconds. More than 2,100 customers around the world rely on Sumo Logic to build, run, and secure their modern applications and cloud infrastructures. Sumo Logic delivers its platform as a true, multi-tenant SaaS architecture, across multiple use-cases, enabling businesses to thrive in the Intelligence Economy.

Media Contact:
Melissa Liton
Sumo Logic
(650) 814-3882

Investor Relations Contact:
Paul Thomas

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2855a365-a14d-499f-94ec-1a2f22b64375

South Korea’s Airport Railroad Express Selects Juniper Networks’ AI-Driven Solutions to Build its All-IP Based Communications Network for Smarter and Safer Operations

Juniper’s MX Series Routers and EX Series Switches driven by Juniper Mist AI will improve overall operational efficiency and enhance passenger safety of the railway

SEOUL, Korea, Sept. 17, 2020 (GLOBE NEWSWIRE) — Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Airport Railroad Express (AREX), a commuter railway connecting South Korea’s international airports to its capital city, has selected Juniper Networks’ solutions for its upgrade to a modern all-IP based communications network. AREX is South Korea’s first domestic railway to feature an all-IP based communications network that integrates wired and wireless networks, enabling efficient network deployment as well as strengthened security and stability through MPLS VPN.

As an important international hub for business and tourism, having efficient transportation infrastructure between the country’s busy ports of entry and the metro urban centers is crucial. Particularly important is connectivity to-and-from Incheon International Airport (ICN), which has consistently been rated as one of the best1 and busiest2 airports in the world, and which has seen continued growth in traffic as one of the largest international gateways into Asia.

Initially launched as a link between ICN and Gimpo International Airport, AREX was expanded directly to Seoul Station in the capital in 2010 and has been providing safe, seamless and convenient connectivity for travelers ever since. With ICN’s continued growth, AREX was looking to further strengthen the railway’s operational efficiency and to keep up with its growing network infrastructure needs.

A major priority was the upgrade of its communication network which plays a vital role in ensuring uninterrupted data transmissions to the railway’s numerous technological systems. This includes systems across signaling, supervisory control and data acquisition, video surveillance and wired/wireless networks.

Juniper Networks was identified and selected for the upgrade – which was to build out a modern IP/MPLS communications network using AI-driven solutions – improving the stability of AREX’s mission-critical systems while supporting the delivery of reliable train services.

News Highlights:

  • Juniper’s routing and switching solutions provide the foundation of AREX’s secure, reliable and flexible all-IP based communications network across multiple deployment sites, while enabling the unified transmission of multiple services
  • The MX960 Universal Routing Platform, alongside the EX9208, EX4600 and EX3400 series of Ethernet Switches, are deployed at the networking control office in AREX’s transmission facility
  • Bringing AI-driven insights, operations and troubleshooting, the EX switches at the transmission facility are enhanced with Wired Assurance, which provides streamlined AI-driven operations, automation and visibility
  • Elsewhere, the MX104 Universal Routing Platform and EX3400 are deployed at the station’s equipment wing
  • AREX has also introduced an integrated operations management system that unifies communication protocols and facility maintenance systems, improving efficiency across operations and fault management
  • AREX can now continuously improve the overall commuting experience with the additional flexibility to expand their IoT infrastructure with extra bandwidth and redundancy

Supporting Quotes:
“Since embarking on this transformational journey, Juniper Networks has proven to be a trusted partner every step of the way. Throughout the duration of this project, they have helped us upgrade the railway’s communications network system without causing any operational disruptions during deployment. They have also delivered trainings to ensure our teams are equipped with the necessary skills to maintain the stability of the network. Our commuters now enjoy an even safer and smoother journey and have not experienced any service disruptions to date. This is testament to Juniper’s AI-driven enterprise solutions that support our growing networking infrastructure demands.”

–  Airport Railroad Express

“A modernized railway communication network has a direct impact on the well-being of commuters and plays a vital role in maintaining operational efficiency and safety. We are proud that our EX Series switches driven by Juniper Mist AI and MX Series routers are at the heart of Airport Rail Road Express’ network and provide the foundation for enhanced customer satisfaction and uncompromised safety standards. Juniper Networks remains committed to helping customers such as AREX in their AI-driven enterprise journey and achieve their strategic goals in the most seamless way possible.”

–   Ki Byung Chai, Country Manager, Korea, Juniper Networks

Additional Resources:

About Juniper Networks
Juniper Networks challenges the inherent complexity that comes with networking and security in the multicloud era. We do this with products, solutions and services that transform the way people connect, work and live. We simplify the process of transitioning to a secure and automated multicloud environment to enable secure, AI-driven networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on TwitterLinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Media Relations:
Satheeson Paramason
Juniper Networks
+65 6511 3595




Lithium Werks ขายผงแคโทด Nanophosphate ให้กับผู้ผลิตแบตเตอรี่ลิเธียม

Lithium Werks, B.V. ประกาศแผนการขายผงแคโทด Nanophosphate® ที่มีชื่อเสียงระดับโลกสำหรับผลิตแบตเตอรี่ลิเธียมให้กับผู้ผลิตแบตเตอรี่ลิเธียม นอกจากนี้ Lithium Werks ยังมอบข้อเสนอเพื่อความบันเทิงสำหรับใบอนุญาตสำหรับสิทธิบัตรกระบวนการผลิต LFP ต้นทุนต่ำทั่วโลก

ออสติน, เท็กซัสและเอ็นสเคอเด , เนเธอร์แลนด์, Sept. 17, 2020 (GLOBE NEWSWIRE) — Lithium Werks มีความยินดีที่จะประกาศว่าขณะนี้ทางบริษัทได้จำหน่ายผง Nanophosphate® ที่ได้รับการจดสิทธิบัตรและเป็นกรรมสิทธิ์ระดับโลก ซึ่งมีผลบังคับใช้ทันที เทคโนโลยีนี้แต่เดิมได้รับการพัฒนาโดย MIT และจากนั้นได้วางจำหน่ายครั้งแรกโดย A123 Systems, Inc. ซึ่ง Lithium Werks ได้รับสิทธิ์ในวัสดุแคโทดที่ปราศจากโคบอลต์ที่จะพลิกโฉมวงการและพร้อมที่จะจำหน่ายผง LFP ชั้นนำนี้ให้กับผู้ผลิตแบตเตอรี่ลิเธียมไอออน ขณะที่บริษัทแบตเตอรี่อื่นๆ กำลังพยายามลดปริมาณโคบอลต์ในแบตเตอรี่ลิเธียมไอออน แต่ Lithium Werks ประสบความสำเร็จในการกำจัดไม่เพียงแต่โคบอลต์เท่านั้น แต่ยังรวมถึงนิกเกิลโลหะหนักที่มีราคาแพง มีการนำ Nanophosphate® มาใช้และผ่านการตรวจสอบแล้วในรถโดยสารไฟฟ้าไฮบริดกว่า 10,000 คันบนท้องถนนเป็นระยะทางหลายล้านไมล์ตั้งแต่ปี 2014 รวมถึงนำไปใช้ในผลิตภัณฑ์ทางการแพทย์ อุตสาหกรรม และการจัดเก็บพลังงานอื่นๆ ในช่วงทศวรรษที่ผ่านมา

“เรามีความยินดีที่จะจำหน่ายผงแคโทด Nanophosphate® ซึ่งเป็นผงลิเธียมไอออนฟอสเฟต (LFP) ชั้นนำของโลก ในขณะที่บริษัทแบตเตอรี่ชั้นนำอื่นๆ กำลังพยายามลดปริมาณโคบอลต์ในแบตเตอรี่ลิเธียม เราได้ข้ามผ่านจุดนั้นมาแล้ว” Joe Fisher ผู้ร่วมก่อตั้งและ CEO ของ Lithium Werks กล่าว “ซึ่งเป็นที่รู้จักกันทั่วโลกในชื่อ Power.Safety.Life. และในด้านต้นทุนรวมในการเป็นเจ้าของที่ต่ำ”

นอกจากนี้ Lithium Werks ยินดีที่จะประกาศว่าทางบริษัทเปิดให้ขอสิทธิ์การใช้งานในสิทธิบัตรกระบวนการผลิต LFP ของตน ซึ่งเป็นกลุ่มผลิตภัณฑ์ที่ประกอบด้วยวิธีการผลิตต้นทุนต่ำในการผลิตวัสดุแคโทดลิเธียมไอออนฟอสเฟต (LFP) ซึ่งเริ่มแรกผ่านการคิดค้นและจดสิทธิบัตรโดย Valence Technology, Inc. และถูกเข้าซื้อโดย Lithium Werks ซึ่งเป็นเจ้าของสิทธิบัตรวัสดุ LFP และเทคโนโลยีที่เกี่ยวข้องที่ใหญ่ที่สุดในโลก

กระบวนการที่จดสิทธิบัตรนี้ได้รับการยอมรับในระดับสากลว่าเป็นวิธีที่คุ้มค่าที่สุดในการผลิตวัสดุแคโทดลิเธียมไอออนฟอสเฟต (LFP) ตามขนาด ปัจจุบัน LFP เป็นวัสดุแคโทดที่ใช้มากที่สุดเป็นอันดับสองของโลกสำหรับแบตเตอรี่ลิเธียมไอออน ซึ่งมีความเกี่ยวข้องเป็นพิเศษในปัจจุบันเนื่องจากปราศจากโคบอลต์ และเป็นที่รู้จักทั่วโลกในเรื่องของพลังงาน ความปลอดภัยและอายุการใช้งานที่ยาวนานเมื่อเทียบกับวัสดุแคโทดลิเธียมไอออนอื่นๆ

“ไม่มี Co หรือ Ni ใน LFP,” Dr. Yazid Saidi, CTO ของ Lithium Werks ซึ่งเป็นผู้ถือสิทธิบัตรหลายรายการในเทคโนโลยี LFP กล่าว “สิทธิบัตรเหล่านี้ รวมถึงสิทธิบัตรกระบวนการช่วยให้สร้างเส้นทางที่โดดเด่นในการผลิตวัสดุแคโทดที่ปรับขนาดได้และประหยัดค่าใช้จ่ายที่จะพลิกโฉมวงการ”

สำหรับข้อมูลเพิ่มเติมเกี่ยวกับการขอรับใบอนุญาตหรือซื้อ Nanophosphate® โปรดติดต่อเราที่: https://lithiumwerks.com/contact/

Lithium Werks ได้รวมความเป็นผู้นำของโลกด้านวัสดุลิเธียมไอออนฟอสเฟต เซลล์ โมดูล และระบบการจัดการแบตเตอรี่ไว้ด้วยกันอย่างค่อยเป็นค่อยไป เป็นหนึ่งในบริษัทแบตเตอรี่ลิเธียมไอออนที่เติบโตเร็วที่สุดในโลก และเป็นผู้นำระดับโลกด้านสิทธิบัตรและผลิตภัณฑ์ LFP โดยมีการดำเนินงานในประเทศจีน ยุโรป และสหรัฐอเมริกา สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Lithium Werks โปรดเยี่ยมชมพวกเราได้ที่ www.lithiumwerks.com


Pulse Secure Expands Global Education Partnerships Into ASEAN

Partnership with Trainocate allows customers and partners to receive localized training which will help to achieve Pulse Secure Technical Expert certification

SINGAPORE, Sept. 16, 2020 (GLOBE NEWSWIRE) — Pulse Secure, the leading provider of software-defined Secure Access solutions, is pleased to announce its new partnership with Trainocate to deliver Pulse Secure Authorized Training courses across ASEAN.

“Our channel has been instrumental to Pulse Secure’s growth as a Zero Trust secure access solution provider,” said Gary Gee, Pulse Secure Regional Channel Manager, ASEAN. “The Trainocate team brings expertise that will further empower our partners to help customers achieve workforce productivity, especially in the context of COVID-19.”

“Pulse Secure is a force to be reckoned with in a Zero Trust world. As businesses navigate the new normal in the current landscape, we anticipate demand for Pulse Secure training to grow,” said April Li, Head, Strategic Portfolio Management at Trainocate. “We’re incredibly excited to be part of the Pulse Secure ecosystem as an authorized education delivery partner and look forward to offering our customers the full spectrum of Pulse Secure trainings.”

Pulse Secure brings together core secure access functions with required interoperability for hybrid IT and multi-cloud. The company’s Zero Trust value proposition is realized through its Access Suite, which delivers protected connectivity, operational intelligence, and threat response across mobile, network, and multi-cloud environments in order to provide easy, compliant access for end users and single-pane-of-glass management for administrators.

The Pulse Secure Training and Certification Program includes training courses designed to help network engineers, enterprise system architects, technical support specialists and implementation consultants to successfully deploy and maintain Pulse Secure products and services. After completing the training course, participants are prepared to take the Pulse Secure Certified Technical Expert exams. Local classes will begin in September 2020 and will include training for: Pulse Policy Secure (PPS) – Deployment, Implementation and ConfigurationPulse Connect Secure (PCS) – Administration and Configuration; Pulse Secure vADC – Foundation and Pulse Secure vADC – Administration and Configuration.

Pulse Partners and customers can find local class offerings by visiting the Trainocate website: https://trainocate.com/courses/Pulse-Secure

Tweet This
@PulseSecure Expands Global Education Partnerships Throughout the ASEAN region. Become a #SecureAccess expert with #PulseSecure & register today.

About Pulse Secure
Pulse Secure provides easy, comprehensive software-driven Secure Access solutions for people, devices, things and services that improve visibility, protection and productivity for our customers. Our suites uniquely integrate cloud, mobile, application and network access to enable hybrid IT in a Zero Trust world. Over 24,000 enterprises and service providers across every vertical entrust Pulse Secure to empower their mobile workforce to securely access applications and information in the data center and cloud while ensuring business compliance. Learn more at www.pulsesecure.net

Follow @PulseSecure on Twitter or visit us on LinkedIn and Facebook.

Media Contact:

Tony Tan
Autonomy for Pulse Secure
+65 6570 9139

Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates

SHANGHAI, China, Sept. 16, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that it has recently entered into a global development, manufacturing and commercialization collaboration with Wigen Biomedicine, a biomedical high-tech company committed to research and development of innovative drugs and new technologies, for Wigen’s 4 cancer drug candidates (XPO1 inhibitor, Aurora-A inhibitor, EGFR-exon20 inhibitor, and 4th generation EGFR inhibitor).

Under the agreement, Wigen Biomedicine will transfer its 50% interest in four of its self-developed drug projects (project code: WJ1024/WJ1075 (either one to be selected by Junshi Biosciences), WJ05129, APL1898, and WJ13404) to Junshi Biosciences. Junshi Biosciences will be granted the world-wide exclusive rights for production and commercialization for these drugs. Junshi Biosciences and Wigen Biomedicine will jointly facilitate the pre-clinical research work of the above drugs in accordance with the agreement. Junshi Biosciences will be responsible for clinical trial applications. Matters such as follow-up clinical trials, drug registration applications and marketing authorization will be determined by the joint steering committee, which is jointly established by both companies. Junshi Biosciences will pay Wigen Biomedicine an upfront fee of RMB 36 million. Wigen Biomedicine is also eligible to receive milestone payments up to RMB 436 million in aggregate, based on the R&D and commercialization progress, and 50% of net profits.

“Wigen Biomedicine is a dynamic and emerging local pharmaceutical technology company. Its idea of focusing on domestic innovative drug development coincides with ours,” said Dr. Li Ning, CEO of Junshi Biosciences. “At present, we have 24 drug candidates in our pipeline. The vast majority of them are innovative drugs, with quite a few having the potential to be first-in-class globally. The collaboration with Wigen will once again expand and strengthen our product layout in oncology, covering even more tumor types. We look forward to working with our partners to bring world-class, trustworthy innovative drugs to patients.”

“As an innovative biomedical company with R&D as its core competency, we must focus on our areas of expertise as well as seek external collaboration. Junshi is a well-known innovation-driven biopharmaceutical company in our industry. Its first domestically produced anti-PD-1 antibody drug, Toripalimab, has been approved and has excellent clinical performance. We believe in Junshi’s rich drug development expertise and commercialization experience complement with our company’s focus on small molecule drug research and development. The collaboration will accelerate our clinical development,” commented Dr. Xie Yuli, CEO of Wigen Biomedicine.

About WJ1024/WJ1075
WJ1024/WJ1075 (either one to be selected by the Company) is an oral broad-spectrum anti-tumor small molecule drug, designed and developed based on the characteristics of covalent inhibitors, which inhibits XPO1 protein with fast metabolism. It can be used clinically for the treatment of a variety of hematological and solid tumors.

About WJ05129
WJ05129 is an oral small molecule Aurora A inhibitor. Aurora A inhibition and RB1 deletion or inactivation are synthetically lethal, which can be used for the treatment of small cell lung cancer, triple negative breast cancer and other malignant tumors with RB1 deletion or inactivation.

About APL1898
APL1898 is a targeted small molecule inhibitor that effectively inhibits EGFR exon20 insertion mutants. Preclinical data show that the drug maintains the activity of inhibiting common EGFR mutants such as T790M while overcoming insensitivity of the third-generation EGFR inhibitors to exon20 insertion mutants.

About WJ13404
WJ13404 is an effective fourth-generation EGFR inhibitor. Preclinical data show that the drug has good inhibitory activity towards acquired EGFR mutants insensitive to the third-generation inhibitors including Del19/T790M/C797S and L858R/T790M/C797S, and is highly selective against wild-type EGFR.

About Wigen Biomedicine
Wigen Biomedicine is a biomedical high-tech company committed to research and development of innovative drugs and new technologies. Its pipeline covers anti-tumor, immunity, metabolism and other therapeutic areas. It has a research and development team of over 40 members, with all core members having doctoral degrees and extensive experience in drug R&D. At present, Wigen Biomedicine has 18 drug candidates and has applied for 24 new drug invention patents.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 26 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurologic, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for PD-1 monoclonal antibody in China and clinical trial application approval for anti PCSK9 monoclonal antibody from NMPA. The world’s first in human anti-BTLA antibody for solid tumors was officially approved for clinical trials by the FDA and NMPA. From this year onwards, Junshi Biosciences pooled its efforts with Chinese science institutions to co-develop JS016, China’s first neutralizing human monoclonal antibodies against SARS-Cov-2, that has entered clinical trial, part of our continuous innovation for disease control and prevention in China and beyond. We have about 2,000 employees in San Francisco and across Maryland in the United States, as well as Shanghai, Suzhou, Beijing, and Guangzhou, China. For more information, please visit: http://junshipharma.com.

Contact Information
IR Team:
Junshi Biosciences
+ 86 021-2250 0300

Solebury Trout
Bob Ai
+ 1 646.389.6658

PR Team:
Junshi Biosciences
Zhi Li
+ 86 021-6105 8800